Αποτελέσματα Αναζήτησης
Lincy LAL | Cited by 1,157 | of University of Texas Health Science Center at Houston, Texas | Read 165 publications | Contact Lincy LAL
In the cur-rent study, we evaluated the real-world use of eltrombopag among patients with ITP secondary to a variety of predis-posing conditions using an electronic health records (EHR) dataset.
We describe healthcare resource utilization (HCRU) and costs in patients with steroid-resistant (SR) cGVHD versus no GVHD up to 360 and 720 days post-HCT.
11 Σεπ 2020 · The second-line of therapy (LOT2) index date was the date of the first prescription for medication (eltrombopag, rituximab, romiplostim) or splenectomy date, collectively referred to as LOT2 index therapy. Patient characteristics were described during the baseline period. Treatment patterns and outcomes were observed in the follow-up period.
Eltrombopag is a well-studied treatment for primary ITP, but evidence is scarce for sITP. We evaluated real-world use of eltrombopag for sITP using electronic health records. Eligible patients had diagnoses of ITP and a qualifying predisposing condition, and eltrombopag treatment.
10 Σεπ 2021 · In the current study, we evaluated the real-world use of eltrombopag among patients with ITP secondary to a variety of predisposing conditions using an electronic health records (EHR) dataset.
2 Μαρ 2021 · Evaluation of treatment patterns and outcomes in patients diagnosed with genitourinary (GU) cancers with linked claims plus prior authorization data. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond.
